4
Clinical Trials associated with Pegfilgrastim biosimilar(Lunan Pharma)Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor secondary prophylaxis in capecitabine combined with oxaliplatin (CapeOX) regimen in the treatment of colorectal cancer
Comparison of efficacy between pegylated recombinant human granulocyte stimulating factor and recombinant human granulocyte stimulating factor in autologous peripheral blood stem cell mobilization in hematologic malignancies
Start Date01 Sep 2020 |
Sponsor / Collaborator- |
聚乙二醇化重组人粒细胞集落刺激因子注射液的有效性和安全性的随机、开放、阳性药平行对照Ⅲb期临床试验
[Translation] A randomized, open-label, positive-drug parallel-controlled phase Ⅲb clinical trial on the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor injection
比较单次皮下注射100μg/kg或6mg固定剂量的PEG-rhG-CSF与每日注射rhG-CSF 5μg/kg/d在乳腺癌化疗患者中的临床有效性和安全性。
[Translation] To compare the clinical efficacy and safety of a single subcutaneous injection of 100 μg/kg or 6 mg fixed dose of PEG-rhG-CSF with daily injection of rhG-CSF 5 μg/kg/d in patients with breast cancer undergoing chemotherapy.
100 Clinical Results associated with Pegfilgrastim biosimilar(Lunan Pharma)
100 Translational Medicine associated with Pegfilgrastim biosimilar(Lunan Pharma)
100 Patents (Medical) associated with Pegfilgrastim biosimilar(Lunan Pharma)
100 Deals associated with Pegfilgrastim biosimilar(Lunan Pharma)